[Webkit-unassigned] [Bug 168774] Add a test verifying cache deduplication is not sensitive to SHA1 collision attack

[bugzilla-daemon at webkit.org]

https://bugs.webkit.org/show_bug.cgi?id=168774

--- Comment #88 from Ashwika <ashwikapatil at gmail.com> ---
We are a 55 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India.

We market our products globally to 75 countries. In the financial year 2015-16, our total income was Rs 25,445 million. Our Indian business contributed 82% to the revenue and the rest was from export of APIs and Finished Dosages.

In India we are recognised for our leadership in the Oral Anti-Diabetic market where we rank No. 1 by Rx and Value. In the Cardiovascular diseases segment we are No. 1 by Rx and rank no. 6 by Value . We also have a significant presence in the areas of Vitamins, Minerals, Nutrients, Dermatology, Gastroenterology and CNS.

Our international business consists of:

A large portfolio of small molecule APIs. Of the 52 products in our portfolio, 27 APIs are commercially available, while others are in various stages of development. Our special skills include production and characterization of polymorphs and particle sizing
A portfolio of Finished Dosages. These include immediate release, modified release and products with 'complex' characteristics which are promoted through ANDA filings and Dossiers linked to supply.
Our spend of 6.1% of sales on R&D ensures that we are able to deliver on our research portfolio. We have over 100,000 sq. ft. of laboratory space with excellent infrastructure. Our research is driven by a team of 345 scientists including 2 doctors, 26 PhDs and 263 post-graduates, many of whom have studied in universities in USA, Europe and Japan. Our intellectual property portfolio consists of patent filings for 31 inventions of which 20 have been granted.



CUSTOM PEPTIDES SYSTHENSIS
http://www.usvindia.com/custom-peptide-synthesis.php
BIOSIMILARS 
http://www.usvindia.com/biosimilars.php
INJECTABLES
http://www.usvindia.com/injectables.php

Ophthalmics
We would be offering 7 products in this category. The following products are at advanced stages of development:

Latanoprost 50 mcg/ml Ophthalmic Solution (Prostaglandin)
Olopatadine HCl 0.1 %Ophthalmic Solution (Anti Histaminic, Allergic Conjunctivitis)
http://www.usvindia.com/ophthalmics.php

PEPTIDES
http://www.usvindia.com/peptides.php

SOLIDS ORALS
Solid Orals
Our solid orals portfolio comprises of immediate release & complex modified release formulations.

10 Solid Orals launched in US & 25 Solid Orals under development or ongoing Pilot/Pivotal bioequivalence studies. These are marketed through our US affiliate Indicus Pharma.
6 Solid Orals launched in Europe and 10 solid oral dossiers are on offer for EU market. 22 solid orals under development or ongoing Pilot/Pivotal bioeqivalence studies.
http://www.usvindia.com/solid-orals.php

-- 
You are receiving this mail because:
You are the assignee for the bug.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.webkit.org/pipermail/webkit-unassigned/attachments/20181215/b6634427/attachment.html>